IFRX
InflaRx N.V.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-16/100
Last price
1.58
▼ 0.10 (5.95%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
1.68
Day high
1.78
Day low
1.57
Volume
720.62K
Market cap
$232.84M
P/E (TTM)
—
52W range
0.80 – 2.95
Trailing performance
Returnvs SPY
1W
-14.59%
-16.5%
1M
-28.83%
-30.0%
3M
-26.85%
-31.4%
6M
+63.39%
+45.2%
YTD
+56.44%
+42.2%
1Y
0.00%
-16.4%
3Y
-46.98%
-129.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on IFRX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
4.34M
Total on file
Fundamentals
Market cap$232.84M
Enterprise value$75.16M
Revenue (TTM)$-10.10K
Gross profit$-4.87M
EBITDA$-35.64M
Net income$-39.14M
EPS (TTM)$-0.58
Free cash flow$-4.31M
Total cash$158.51M
Total debt$833.18K
Book value / share$1.12
Shares outstanding147.37M
Float98.11M
Short % of float8.96%
Dividend yield0.00%
Beta (5Y)2.61
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.06
PEG ratio—
Price / sales—
Price / book1.42
EV / revenue-7,440.90
EV / EBITDA-2.11
Gross margin0.00%
Operating margin352965.00%
Profit margin0.00%
Return on equity-38.52%
Return on assets-18.54%
Debt / equity0.57
Current ratio8.22
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $29.33K | $165.79K | $63.09K | $0 | -82.3% |
| Operating revenue | $29.33K | $165.79K | $63.09K | $0 | -82.3% |
| Cost of revenue | $7.27M | $3.32M | $532.26K | $0 | +119.1% |
| Gross profit | -$7.24M | -$3.15M | -$469.17K | $0 | -129.7% |
| Research & development | $25.72M | $35.36M | $41.02M | $37.53M | -27.3% |
| Selling, general & admin | $17.56M | $19.33M | $16.12M | $14.34M | -9.1% |
| Total operating expense | $41.02M | $49.75M | $44.13M | $32.24M | -17.6% |
| Operating income | -$48.26M | -$52.91M | -$44.59M | -$32.24M | +8.8% |
| Net interest income | $1.81M | $3.18M | $3.77M | $310.96K | -43.1% |
| Pre-tax income | -$45.62M | -$46.06M | -$42.67M | -$29.48M | +1.0% |
| Tax provision | $12.28K | $5.22K | $0 | $0 | +135.4% |
| Net income | -$45.63M | -$46.06M | -$42.67M | -$29.48M | +0.9% |
| Net income to common | -$45.63M | -$46.06M | -$42.67M | -$29.48M | +0.9% |
| Basic EPS | -0.68 | -0.78 | -0.78 | -0.67 | +12.8% |
| Diluted EPS | -0.68 | -0.78 | -0.78 | -0.67 | +12.8% |
| EBIT | -$45.58M | -$46.04M | -$42.63M | -$29.44M | +1.0% |
| EBITDA | -$45.16M | -$45.55M | -$42.06M | -$28.84M | +0.9% |
| Basic shares | 67.29M | 58.92M | 54.94M | 44.21M | +14.2% |
| Diluted shares | 67.29M | 58.92M | 54.94M | 44.21M | +14.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $16.02M | $18.38M | $12.77M | $16.27M | -12.8% |
| Cash & short-term investments | $46.46M | $52.84M | $90.27M | $81.81M | -12.1% |
| Inventory | $0 | $6.90M | $11.37M | $0 | -100.0% |
| Total current assets | $53.63M | $71.66M | $109.47M | $97.41M | -25.2% |
| Property, plant & equipment | $1.15M | $1.01M | $1.36M | $1.64M | +13.4% |
| Goodwill & intangibles | $42.26K | $50.78K | $68.82K | $138.91K | -16.8% |
| Total assets | $55.22M | $76.02M | $120.21M | $102.40M | -27.4% |
| Total current liabilities | $12.98M | $14.17M | $16.84M | $13.03M | -8.4% |
| Total debt | $897.92K | $805.09K | $1.12M | $1.36M | +11.5% |
| Total liabilities | $13.66M | $14.60M | $17.63M | $14.05M | -6.5% |
| Retained earnings | -$377.83M | -$332.19M | -$286.13M | -$243.46M | -13.7% |
| Shareholder equity | $41.56M | $61.42M | $102.58M | $88.35M | -32.3% |
| Working capital | $40.65M | $57.49M | $92.62M | $84.39M | -29.3% |
| Net tangible assets | $41.51M | $61.37M | $102.51M | $88.21M | -32.3% |
| Shares issued | 72.29M | 59.35M | 58.88M | 44.70M | +21.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$45.63M | -$46.06M | -$42.67M | -$29.48M | +0.9% |
| Depreciation & amortisation | $419.48K | $485.11K | $567.78K | $596.60K | -13.5% |
| Stock-based compensation | $4.44M | $4.07M | $3.41M | $6.04M | +9.3% |
| Change in working capital | $4.86M | -$2.28M | $1.00M | -$9.77M | +313.1% |
| Operating cash flow | -$35.31M | -$48.56M | -$37.81M | -$33.74M | +27.3% |
| Capital expenditure | -$115.69K | -$46.87K | -$81.10K | -$162.39K | -146.8% |
| Investing cash flow | $3.23M | $52.36M | -$17.70M | $19.36M | -93.8% |
| Financing cash flow | $33.32M | $386.45K | $52.99M | $1.94M | +8,521.3% |
| Free cash flow | -$35.43M | -$48.60M | -$37.89M | -$33.91M | +27.1% |
| End cash position | $16.02M | $18.38M | $12.77M | $16.27M | -12.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | -$33.93K | $23.83K | $39.43K | — | — |
| Operating revenue | $0 | $0 | -$33.93K | $23.83K | $39.43K | — | — |
| Cost of revenue | $0 | $0 | $4.86M | $333 | $2.40M | — | — |
| Gross profit | $0 | $0 | -$4.89M | $23.50K | -$2.36M | — | — |
| Research & development | $4.74M | $4.17M | $5.26M | $6.24M | $7.20M | — | +13.6% |
| Selling, general & admin | $2.53M | $3.29M | $2.96M | $3.79M | $4.31M | — | -23.0% |
| Total operating expense | $7.00M | $7.21M | $7.96M | $9.50M | $10.58M | — | -2.8% |
| Operating income | -$7.00M | -$7.21M | -$12.86M | -$9.48M | -$12.94M | — | +2.8% |
| Net interest income | $756.02K | $1.12M | -$3.41M | -$2.75M | $518.87K | — | -32.7% |
| Pre-tax income | -$10.60M | -$5.59M | -$10.64M | -$12.25M | -$14.44M | — | -89.5% |
| Tax provision | $0 | $0 | $0 | $12.28K | $0 | — | — |
| Net income | -$10.65M | -$5.59M | -$10.64M | -$12.26M | -$14.42M | — | -90.4% |
| Net income to common | -$10.65M | -$5.59M | -$10.64M | -$12.26M | -$14.42M | — | -90.4% |
| Basic EPS | -0.09 | -0.08 | — | -0.18 | -0.21 | -0.13 | -12.5% |
| Diluted EPS | -0.09 | -0.08 | — | -0.18 | -0.21 | -0.13 | -12.5% |
| EBIT | -$10.59M | -$5.58M | -$10.62M | -$12.23M | -$14.43M | — | -89.8% |
| EBITDA | -$10.49M | -$5.49M | -$10.53M | -$12.13M | -$14.32M | — | -91.1% |
| Basic shares | 117.66M | 72.29M | — | 67.75M | 67.75M | 63.31M | +62.8% |
| Diluted shares | 117.66M | 72.29M | — | 67.75M | 67.75M | 63.31M | +62.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $146.57M | $14.99M | $16.02M | $6.45M | $13.00M | — | +877.5% |
| Cash & short-term investments | $158.51M | $39.80M | $46.46M | $44.65M | $48.00M | — | +298.3% |
| Inventory | — | — | $0 | $5.07M | $5.04M | $6.90M | — |
| Total current assets | $165.40M | $47.40M | $53.63M | $63.47M | $66.17M | — | +249.0% |
| Property, plant & equipment | $1.07M | $1.07M | $1.15M | $1.24M | $806.31K | — | +0.0% |
| Goodwill & intangibles | $78.12K | $45.60K | $42.26K | $46.18K | $50.11K | — | +71.3% |
| Total assets | $166.91M | $48.89M | $55.22M | $65.16M | $73.44M | — | +241.4% |
| Total current liabilities | $20.13M | $11.39M | $12.98M | $19.05M | $16.16M | — | +76.7% |
| Total debt | $833.18K | $823.03K | $897.92K | $970.86K | $599.11K | — | +1.2% |
| Total liabilities | $20.72M | $12.00M | $13.66M | $19.79M | $16.40M | — | +72.7% |
| Retained earnings | -$394.07M | -$383.42M | -$377.83M | -$367.18M | -$354.92M | — | -2.8% |
| Shareholder equity | $146.18M | $36.89M | $41.56M | $45.37M | $57.04M | — | +296.3% |
| Working capital | $145.27M | $36.01M | $40.65M | $44.41M | $50.02M | — | +303.5% |
| Net tangible assets | $146.11M | $36.84M | $41.51M | $45.32M | $56.99M | — | +296.5% |
| Shares issued | 147.37M | 72.29M | 72.29M | 67.75M | 67.75M | — | +103.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$10.65M | -$5.59M | -$10.64M | -$12.26M | -$14.42M | -90.4% |
| Depreciation & amortisation | $92.08K | $87.18K | $90.89K | $99.79K | $115.00K | +5.6% |
| Stock-based compensation | $591.38K | $941.10K | $260.25K | $595.88K | $1.11M | -37.2% |
| Change in working capital | $1.42M | -$1.44M | $7.50M | -$765.67K | $3.37M | +198.8% |
| Operating cash flow | -$2.57M | -$7.39M | -$4.71M | -$9.04M | -$7.55M | +65.2% |
| Capital expenditure | -$36.45K | -$9.47K | -$2.05K | -$87.97K | -$15.23K | -285.0% |
| Investing cash flow | $12.85M | $6.14M | $7.88M | $2.60M | -$24.91M | +109.4% |
| Financing cash flow | $119.29M | -$74.69K | $6.49M | -$84.95K | -$99.81K | +159,817.4% |
| Free cash flow | -$2.61M | -$7.40M | -$4.71M | -$9.13M | -$7.57M | +64.8% |
| End cash position | $146.57M | $14.99M | $16.02M | $6.45M | $13.00M | +877.5% |
Options analytics
Put / call volume
0.11
Call-heavy session
Put / call open interest
0.04
Positioning, not flow
Max pain
0.50
-68.4% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
208
Contracts, this expiry
Put volume
23
Contracts, this expiry
Heaviest call OI
7.50
93 contracts
Heaviest put OI
0.50
4 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.06 | -0.09 | -63.6% |
| Mar 2026 | -0.15 | -0.08 | +45.8% |
| Dec 2025 | -0.15 | -0.15 | -2.7% |
| Sep 2025 | -0.12 | -0.18 | -46.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.05 | 5 | $0 | -100.0% |
| Next quarter | -0.05 | 5 | $0 | +100.0% |
| Current year | -0.27 | 5 | $0 | -100.0% |
| Next year | -0.35 | 5 | $0 | 0.0% |
Analyst targets & ownership
Mean target$7.65
High target$13.60
Low target$2.91
Implied upside384.10%
Analyst count9
ConsensusNONE
Strong buy / Buy1 / 7
Hold1
Sell / Strong sell0 / 0
Held by insiders2.95%
Held by institutions70.39%
Institutions holding70
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.79
-11.93% from price
SMA 20
1.93
-18.35% from price
SMA 50
1.99
-20.57% from price
SMA 100
2.02
-21.72% from price
SMA 200
1.59
-0.87% from price
EMA 12
1.81
-12.67% from price
EMA 26
1.92
-17.70% from price
EMA 50
1.96
-19.44% from price
RSI (14)
26.8
Oversold
MACD (12,26,9)
-0.11
Hist -0.04
ATR (14)
0.13
7.97% of price
Realised vol 30D
72.1%
Annualised
Bollinger upper
2.26
20, 2σ
Bollinger lower
1.61
20, 2σ
50 / 200 cross
Golden
1.99 vs 1.59
Trend bias
Below 200
-0.87%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.27
More volatile than market
Correlation to SPY
0.30
Loosely linked
Realised vol 30D
72.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-50.3%
Peak to trough
Max drawdown 5Y
-88.0%
Peak to trough
ATR 14
0.13
7.97% of price
Beta (reported)
2.61
5Y monthly, from filing
Short interest
Shares short
12.11M
Prior 9.46M
Change vs prior
+27.9%
Shorts adding
% of float
8.96%
Normal
% of shares out
8.22%
Against total outstanding
Days to cover
15.1
Crowded exit
Float
98.11M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 14, 26 | Needham | INITIATED | — | Buy |
| Aug 7, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| May 13, 26 | Raymond James | UPGRADE | Outperform | Strong Buy |
| May 11, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 11, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Apr 21, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Mar 20, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Dec 30, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 3, 25 | Leerink Partners | DOWNGRADE | Outperform | Market Perform |
| Nov 10, 25 | Guggenheim | MAINTAINED | Buy | Buy |
| May 29, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| May 8, 25 | Oppenheimer | INITIATED | — | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-08-06
Corporate Changes & Voting Matters
6-K · 2026-06-30
Corporate Changes & Voting Matters
6-K · 2026-05-07
Corporate Changes & Voting Matters
6-K · 2026-05-04
Corporate Changes & Voting Matters
6-K · 2026-04-28
Corporate Changes & Voting Matters
6-K · 2026-04-23
Corporate Changes & Voting Matters
6-K · 2026-04-09
Corporate Changes & Voting Matters
6-K · 2026-04-02
Headlines
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
GlobeNewswire · 5d ago
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
GlobeNewswire · 6d ago
InflaRx to Host Virtual Capital Markets Day
GlobeNewswire · 16d ago
Needham Initiates InflaRx at Buy With $8 Price Target
MT Newswires · 23d ago
InflaRx Announces Participation in September Investor Conferences
GlobeNewswire · 48d ago
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
GlobeNewswire · 62d ago
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
Zacks · 64d ago
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
GlobeNewswire · 69d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.